Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Debt / NOTE 2.250% 2/0
-
Market price (% of par)
-
112.61%
-
Total 13F principal
-
$180,829,220
-
Principal change
-
+$51,361,000
-
Total reported market value
-
$205,186,247
-
Number of holders
-
14
-
Value change
-
+$58,009,065
-
Number of buys
-
4
-
Number of sells
-
5
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 as of Q4 2025
As of 31 Dec 2025,
BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 was held by
14 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$180,829,220
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, MACKAY SHIELDS LLC, ADVENT CAPITAL MANAGEMENT /DE/, Nuveen, LLC, SHENKMAN CAPITAL MANAGEMENT INC, SSI INVESTMENT MANAGEMENT LLC, Calamos Advisors LLC, RWC Asset Management LLP, GOLDMAN SACHS GROUP INC, and JPMORGAN CHASE & CO.
This page lists
14
institutional bondholders reporting positions
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.